Molecular and histopathology directed therapy for advanced bladder cancer
C Alifrangis, U McGovern, A Freeman, T Powles… - Nature Reviews …, 2019 - nature.com
Bladder cancer is a heterogeneous group of tumours with at least 40 histological subgroups.
Patients with localized disease can be cured with surgical resection or radiotherapy, but …
Patients with localized disease can be cured with surgical resection or radiotherapy, but …
Extracellular vesicles swarm the cancer microenvironment: from tumor–stroma communication to drug intervention
F Wendler, R Favicchio, T Simon, C Alifrangis… - Oncogene, 2017 - nature.com
Intercellular communication sets the pace for transformed cells to survive and to thrive.
Extracellular vesicles (EVs), such as exosomes, microvesicles and large oncosomes, are …
Extracellular vesicles (EVs), such as exosomes, microvesicles and large oncosomes, are …
Langerhans cell histiocytosis: old disease new treatment
…, C O'Hanlon-Brown, C Alifrangis… - … Journal of Medicine, 2011 - academic.oup.com
Langerhans cell histiocytosis (LCH) has been previously thought of as a rare illness, but is
now increasingly diagnosed as a result of the more intensive investigations of patients with …
now increasingly diagnosed as a result of the more intensive investigations of patients with …
ctDNA monitoring using patient-specific sequencing and integration of variant reads
…, C Caldas, DM Rassl, RC Rintoul, C Alifrangis… - Science translational …, 2020 - science.org
Circulating tumor-derived DNA (ctDNA) can be used to monitor cancer dynamics noninvasively.
Detection of ctDNA can be challenging in patients with low-volume or residual disease, …
Detection of ctDNA can be challenging in patients with low-volume or residual disease, …
[PDF][PDF] EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis
C Alifrangis, R Agarwal, D Short… - Journal of clinical …, 2013 - researchgate.net
Purpose Patients with high-risk (International Federation of Gynecology and Obstetrics score
7) gestational trophoblastic neoplasia (GTN) frequently receive etoposide, methotrexate, …
7) gestational trophoblastic neoplasia (GTN) frequently receive etoposide, methotrexate, …
Inactivating CUX1 mutations promote tumorigenesis
…, C Alifrangis, LB Alexandrov, JC Tiffen, C Kober… - Nature …, 2014 - nature.com
A major challenge in cancer genetics is to determine which low-frequency somatic mutations
are drivers of tumorigenesis. Here we interrogate the genomes of 7,651 diverse human …
are drivers of tumorigenesis. Here we interrogate the genomes of 7,651 diverse human …
BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model
… (C) Number of tumors developed in the cohort of 4-OHT–treated BCTSB13 mice; 70% of the
mice developed more than one tumor. (D) Melanomas of 4-OHT–treated BCTSB13 mice first …
mice developed more than one tumor. (D) Melanomas of 4-OHT–treated BCTSB13 mice first …
[HTML][HTML] The identification of plasma exosomal miR-423-3p as a potential predictive biomarker for prostate cancer castration-resistance development by plasma …
…, S Kudahetti, T Oliver, T Powles, C Alifrangis… - Frontiers in Cell and …, 2021 - frontiersin.org
Castration-resistant prostate cancer (CRPC) is the major cause of death from prostate
cancer. Biomarkers to improve early detection and prediction of CRPC especially using non-…
cancer. Biomarkers to improve early detection and prediction of CRPC especially using non-…
[HTML][HTML] BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib
M Ranzani, C Alifrangis, D Perna… - Pigment cell & …, 2015 - ncbi.nlm.nih.gov
… (C) The sensitivity to trametinib of NF1 negative melanoma cell lines is comparable to
those that express NF1. Data are graphed as in A. (D) Treatment with trametinib at escalating …
those that express NF1. Data are graphed as in A. (D) Treatment with trametinib at escalating …
A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections
…, P Baldwin, R Knight, J Shamash, C Alifrangis… - World Journal of …, 2022 - Springer
Purpose To describe and compare differences in peri-operative outcomes of robot-assisted (RA-RPLND)
and open (O-RPLND) retroperitoneal lymph node dissection performed by a …
and open (O-RPLND) retroperitoneal lymph node dissection performed by a …